The global Charles Bonnet Syndrome market size was valued at USD 310.00 Million in 2025 and is expected to reach USD 497.83 Million by 2033, at a CAGR of 6.10% during the forecast period
The market growth is largely fueled by increasing awareness of visual impairment-related neurological conditions, continuous advancements in diagnostic technologies, and growing digitalization across healthcare systems, ophthalmology centers, and neurology clinics
Furthermore, rising demand for effective, patient-friendly, and integrated treatment approaches for vision loss-associated hallucination disorders is establishing Charles Bonnet Syndrome solutions as an important component of modern neurological and ophthalmic care. These converging factors are accelerating the uptake of Charles Bonnet Syndrome solutions, thereby significantly boosting the industry's growth